Search
Vyne Therapeutics Inc
VYNEAdd to Watchlist
0.671USD
+0.001+0.09%
Market hours （ET）Quotes delayed by 15 min
22.36MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+0.09%
5 Days
-0.37%
1 Month
+7.72%
6 Months
+79.22%
Year to Date
+15.67%
1 Year
-46.75%
TradingKey Stock Score of Vyne Therapeutics Inc
Currency: USD Updated: 2026-05-14Key Insights
Vyne Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 175 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vyne Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Vyne Therapeutics Inc Highlights
StrengthsRisks
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 570.00K.
Undervalued
The company’s latest PE is -1.08, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.08M shares, decreasing 13.12% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.000
Target Price
+198.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vyne Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vyne Therapeutics Inc Info
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Ticker SymbolVYNE
CompanyVyne Therapeutics Inc
CEODomzalski (David)
Websitehttps://vynetherapeutics.com/
Related Instruments
+0.45%
-1.85%
-0.60%
+0.63%
-0.28%
-1.50%
-1.67%
-1.38%
-2.10%
-1.05%
-0.83%
-1.60%
+0.64%
-2.56%
+1.78%
0.00%
-2.02%
0.00%
-1.63%
+1.09%Popular Instruments
100.960
+2.097 (+2.12%)
300.920
+2.710 (+0.91%)
226.535
-9.205 (-3.90%)
4559.180
-91.050 (-1.96%)
474.077
-15.073 (-3.08%)
1395.990
+13.270 (+0.96%)
733.470
-42.540 (-5.48%)
397.630
-3.440 (-0.86%)
79299.410
-2082.630 (-2.56%)
426.740
-16.560 (-3.74%)
